Galapagos NV ADR(GLPG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 4.65 | EPS (ttm) | 5.96 | Insider Own | 25.35% | Shs Outstand | 65.9M | Perf Week | -0.36% |
| Market Cap | 1.83B | Forward P/E | - | EPS next Y | 19.26% | Insider Trans | - | Shs Float | 49.2M | Perf Month | -4.02% |
| Enterprise Value | -1.69B | PEG | - | EPS next Q | -0.82 | Inst Own | 22% | Short Float | 2.79% | Perf Quarter | -16.93% |
| Income | 0.39B | P/S | 1.42 | EPS this Y | -137.86% | Inst Trans | -11.44% | Short Ratio | 9.08 | Perf Half Y | -8.96% |
| Sales | 1.28B | P/B | 0.48 | EPS next 5Y | - | ROA | 9.45% | Short Interest | 1.37M | Perf YTD | -15.2% |
| Book/sh | 57.67 | P/C | 0.52 | EPS past 3/5Y | - | ROE | 11.51% | 52W High | -26.6% ($37.78) | Perf Year | 7.48% |
| Cash/sh | 53.43 | P/FCF | - | Sales past 3/5Y | 70.43% 18.16% | ROIC | 10.32% | 52W Low | 12.11% ($24.74) | Perf 3Y | -35.35% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 396.11% | Gross Margin | 97.43% | Volatility(W/M) | 2.01% 1.87% | Perf 5Y | -63.05% |
| Dividend TTM | - | EV/Sales | -1.31 | Sales Y/Y TTM | 331.24% | Oper. Margin | 44.13% | ATR (14) | 0.72 | Perf 10Y | -39.51% |
| Dividend Ex-Date | - | Quick Ratio | 19.96 | EPS Q/Q | 3271.88% | Profit Margin | 30.58% | RSI (14) | 36.52 | Recom | 3.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 20.11 | Sales Q/Q | 1201.99% | SMA20 | -2.99% ($28.58) | Beta | 0.25 | Target Price | $33.11 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/5/6 | SMA50 | -8.55% ($30.32) | Rel Volume | 1.91 | Prev Close | $28.81 |
| Employees | 452 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 126.27% -72.1% | SMA200 | -13.74% ($32.15) | Avg Volume(3M) | 0.15M | Price | $27.73 |
| IPO | 2008/7/7 | Option/Short | Yes/Yes | Trades | 3880 | Volume | 288,106 | Change | -3.75% |
🧬 An innovative Belgian-based biotech company developing next-generation CAR-T cell therapies and novel drugs for autoimmune diseases. It possesses proprietary 'decentralized manufacturing platform' technology capable of producing therapies in just 7 days, and is pursuing aggressive pipeline expansion backed by a massive cash position exceeding €3 billion.
Over the past 1 year, on the lower side
27% below its 1-year high.
Traded more than usual. That is 191% of its average volume.
GLPG makes money exceptionally well
Of every $100 in sales, $44.13 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -137.9% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $465. Peers typically go for $512.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -63.0%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 22.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #108 of 598 in the industry
Based on market cap of $2B.
VIR#105 Vir Biotechnology Inc $2B PER - 
REPL#106 Replimune Group Inc $2B PER - 
PGEN#107 Precigen Inc $2B PER - GLPG#108 Galapagos NV ADR $2B PER 4.7 
ZBIO#108 Zenas Biopharma Inc $2B PER - 
FAQ
What kind of company is GLPG?
GLPG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GLPG?
The market cap of GLPG is approximately $1.8B, ranking 2,146 within its sector.
What is the P/E ratio of GLPG?
GLPG has a P/E ratio of approximately 4.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for GLPG?
GLPG has recorded a 52-week high of $37.78 and a low of $24.74.
